Background/Aims: Progesterone (P4) fall provoked by spontaneous or prostaglandin F2α (PGF2α)-induced luteolysis in late pregnant rats triggers a prolactin (PRL) surge 12–24 h later. Methods: To investigate the hypothalamic mechanism mediating this response, we determined expression of tyrosine hydroxylase (TH), PRL receptors (long form, PRLRlong), estrogen-α (ERα) and ERβ, P4 (PR) A and B receptors, and STAT5a, STAT5b, suppressors of cytokine signaling 1 (SOCS1), SOCS3 and CIS at mRNA (by semiquantitative and real-time RT-PCR) and protein (by Western blot only for TH, ERα and PRs) levels, and dopamine and DOPAC (by high-performance liquid chromatography) contents in the mediobasal hypothalamus (MBH) 24 h after luteolysis induced by a PGF2α analogue (cloprostenol, 25 µg/rat s.c. at 8 and 12 h on day 19 of pregnancy). Results: PGF2α treatment decreased circulating P4 and estradiol and increased PRL and the estradiol/P4 ratio. MBH DOPAC and DOPAC/dopamine ratio fell, indicating decreased dopaminergic transmission. PRLRlong, PRB and ERα mRNA increased. ERα and PR proteins were not modified. However, TH protein and mRNA did not change. PRA, the small PR isoform, was much more abundant than PRB, the isoform considered to mediate P4 genomic actions. STAT5a, SOCS1 and SOCS3 mRNA were also increased. Conclusion: The P4 fall induced by PGF2α treatment induces PRL release through diminution in MBH dopaminergic transmission without change in TH expression. The increased PRLR along with elevated circulating PRL may be responsible for maintaining high TH expression through activation of short-loop feedback mechanisms, counteracting the effect of the fall in circulating P4. In parallel, SOCS expression contributes to limit PRL signaling.

1.
Freeman ME, Kanyicska B, Lerant A, Nagy G: Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523–1631.
2.
Zigmond RE, Schwarzschild MA, Rittenhouse AR: Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu Rev Neurosci 1989;12:415–461.
3.
Grattan DR, Steyn FJ, Kokay IC, Anderson GM, Bunn SJ: Pregnancy-induced adaptation in the neuroendocrine control of prolactin secretion. J Neuroendocrinol 2008;20:497–507.
4.
Grattan DR, Averill RL: Effect of ovarian steroids on a nocturnal surge of prolactin secretion that precedes parturition in the rat. Endocrinology 1990;126:1199–1205.
5.
Jahn GA, Alonso N, Deis RP: Ovarian and feto-placental factors and the regulation of prolactin release during pregnancy in the rat. J Reprod Fertil 1986;77:125–133.
6.
Andrews ZB, Grattan DR: The roles of dopamine and the neurointermediate lobe of the pituitary in the regulation of prolactin secretion during late pregnancy in rats. J Neuroendocrinol 2004;16:859–865.
7.
Valdez SR, Penissi AB, Deis RP, Jahn GA: Hormonal profile and reproductive performance in lactation deficient (OFA hr/hr) and normal (Sprague-Dawley) female rats. Reproduction 2007;133:827–840.
8.
Andrews ZB, Kokay IC, Grattan DR: Dissociation of prolactin secretion from tuberoinfundibular dopamine activity in late pregnant rats. Endocrinology 2001;142:2719–2724.
9.
Steyn FJ, Anderson GM, Grattan DR: Hormonal regulation of suppressors of cytokine signaling (SOCS) messenger ribonucleic acid in the arcuate nucleus during late pregnancy. Endocrinology 2008;149:3206–3214.
10.
Anderson GM, Beijer P, Bang AS, Fenwick MA, Bunn SJ, Grattan DR: Suppression of prolactin-induced signal transducer and activators of transcription 5b signaling and induction of suppressors of cytokine signaling messenger ribonucleic acid in the hypothalamic arcuate nucleus of the rat during late pregnancy and lactation. Endocrinology 2006;147:4996–5005.
11.
Lee Y, Voogt JL: Feedback effects of placental lactogens on prolactin levels and Fos-related antigen immunoreactivity of tuberoinfundibular dopaminergic neurons in the arcuate nucleus during pregnancy in the rat. Endocrinology 1999;140:2159–2166.
12.
Liu B, Arbogast LA: Gene expression profiles of intracellular and membrane progesterone receptor isoforms in the mediobasal hypothalamus during pro-oestrus. J Neuroendocrinol 2009;21:993–1000.
13.
Lonstein JS, Blaustein JD: Immunocytochemical investigation of nuclear progestin receptor expression within dopaminergic neurones of the female rat brain. J Neuroendocrinol 2004;16:534–543.
14.
Pi XJ, Grattan DR: Increased expression of both short and long forms of prolactin receptor mRNA in hypothalamic nuclei of lactating rats. J Mol Endocrinol 1999;23:13–22.
15.
Hou Y, Yang SP, Voogt JL: Changes in estrogen receptor-alpha expression in hypothalamic dopaminergic neurons during proestrous prolactin surge. Endocrine 2003;20:131–138.
16.
Francis K, Meddle SL, Bishop VR, Russell JA: Progesterone receptor expression in the pregnant and parturient rat hypothalamus and brainstem. Brain Res 2002;927:18–26.
17.
Lerant A, Freeman ME: Ovarian steroids differentially regulate the expression of PRL-R in neuroendocrine dopaminergic neuron populations: a double label confocal microscopic study. Brain Res 1998;802:141–154.
18.
Blum M, McEwen BS, Roberts JL: Transcriptional analysis of tyrosine hydroxylase gene expression in the tuberoinfundibular dopaminergic neurons of the rat arcuate nucleus after estrogen treatment. J Biol Chem 1987;262:817–821.
19.
Jones EE, Naftolin F: Estrogen effects on the tuberoinfundibular dopaminergic system in the female rat brain. Brain Res 1990;510:84–91.
20.
Rance N, Wise PM, Barraclough CA: Negative feedback effects of progesterone correlated with changes in hypothalamic norepinephrine and dopamine turnover rates, median eminence luteinizing hormone-releasing hormone, and peripheral plasma gonadotropins. Endocrinology 1981;108:2194–2199.
21.
Cramer OM, Parker CR Jr, Porter JC: Stimulation of dopamine release into hypophysial portal blood by administration of progesterone. Endocrinology 1979;105:929–933.
22.
Arbogast LA, Voogt JL: Progesterone reverses the estradiol-induced decrease in tyrosine hydroxylase mRNA levels in the arcuate nucleus. Neuroendocrinology 1993;58:501–510.
23.
Vermouth NT, Deis RP: Prolactin release induced by prostaglandin F2 in pregnant rats. Nat New Biol 1972;238:248–250.
24.
Jahn GA, Kalia V, Hole D, Wilson CA, Deis RP: Receptors and neurotransmitters involved in the dual modulation of prolactin release by the serotoninergic system in pregnant and lactating rats. J Reprod Fertil 1999;116:261–268.
25.
Soaje M, Valdez S, Bregonzio C, Penissi A, Deis RP: Dopaminergic mechanisms involved in prolactin release after mifepristone and naloxone treatment during late pregnancy in the rat. Neuroendocrinology 2006;84:58–67.
26.
Soaje M, Bregonzio C, Caron RW, Deis RP: Neurotransmitters involved in the opioid regulation of prolactin secretion at the end of pregnancy in rats. Neuroendocrinology 2004;80:11–20.
27.
Jahn GA, Deis RP: Involvement of the adrenergic system on the release of prolactin and lactogenesis at the end of pregnancy in the rat. J Endocrinol 1991;129:343–350.
28.
Snedecor GW, Cochran WG: Statistical Methods, ed 6. Ames, Iowa State University Press, 1968.
29.
Bussmann LE, Deis RP: Studies concerning the hormonal induction of lactogenesis by prostaglandin F2 alpha in pregnant rats. J Steroid Biochem 1979;11:1485–1489.
30.
Ben Jonathan N, Hnasko R: Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001;22:724–763.
31.
Grattan DR, Averill RL: Role of the placenta in the control of the ante-partum surge of prolactin in the rat. J Endocrinol 1991;130:401–407.
32.
Grattan DR, Averill RL: Absence of short-loop autoregulation of prolactin during late pregnancy in the rat. Brain Res Bull 1995;36:413–416.
33.
Deis RP, Carrizo DG, Jahn GA: Suckling-induced prolactin release potentiates mifepristone-induced lactogenesis in pregnant rats. J Reprod Fertil 1989;87:147–153.
34.
Andrews ZB: Neuroendocrine regulation of prolactin secretion during late pregnancy: easing the transition into lactation. J Neuroendocrinol 2005;17:466–473.
35.
Sar M: Distribution of progestin-concentrating cells in rat brain: colocalization of [3H]ORG.2058, a synthetic progestin, and antibodies to tyrosine hydroxylase in hypothalamus by combined autoradiography and immunocytochemistry. Endocrinology 1988;123:1110–1118.
36.
Fox SR, Harlan RE, Shivers BD, Pfaff DW: Chemical characterization of neuroendocrine targets for progesterone in the female rat brain and pituitary. Neuroendocrinology 1990;51:276–283.
37.
Arbogast LA, Voogt JL: Progesterone induces dephosphorylation and inactivation of tyrosine hydroxylase in rat hypothalamic dopaminergic neurons. Neuroendocrinology 2002;75:273–281.
38.
Liu B, Arbogast LA: Progesterone decreases tyrosine hydroxylase phosphorylation state and increases protein phosphatase 2A activity in the stalk-median eminence on proestrous afternoon. J Endocrinol 2010;204:209–219.
39.
Arbogast LA, Voogt JL: Hyperprolactinemia increases and hypoprolactinemia decreases tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nuclei, but not the substantia nigra or zona incerta. Endocrinology 1991;128:997–1005.
40.
Fliestra RJ, Voogt JL: Lactogenic hormones of the placenta and pituitary inhibit suckling-induced prolactin (PRL) release but not the ante-partum PRL surge. Proc Soc Exp Biol Med 1997;214:258–264.
41.
Lerant A, Kanyicska B, Freeman ME: Nuclear translocation of STAT5 and increased expression of Fos related antigens (FRAs) in hypothalamic dopaminergic neurons after prolactin administration. Brain Res 2001;904:259–269.
42.
Grattan DR, Xu JJ, McLachlan MJ, Kokay IC, Bunn SJ, Hovey RC, Davey HW: Feedback regulation of PRL secretion is mediated by the transcription factor, signal transducer, and activator of transcription 5b. Endocrinology 2001;142:3935–3940.
43.
Ma FY, Anderson GM, Gunn TD, Goffin V, Grattan DR, Bunn SJ: Prolactin specifically activates STAT5b in neuroendocrine dopaminergic neurons. Endocrinology 2005;146:5112–5119.
44.
Pi X, Zhang B, Li J, Voogt JL: Promoter usage and estrogen regulation of prolactin receptor gene in the brain of the female rat. Neuroendocrinology 2003;77:187–197.
45.
Augustine RA, Kokay IC, Andrews ZB, Ladyman SR, Grattan DR: Quantitation of prolactin receptor mRNA in the maternal rat brain during pregnancy and lactation. J Mol Endocrinol 2003;31:221–232.
46.
Kokay IC, Grattan DR: Expression of mRNA for prolactin receptor (long form) in dopamine and pro-opiomelanocortin neurones in the arcuate nucleus of non-pregnant and lactating rats. J Neuroendocrinol 2005;17:827–835.
47.
Gabutti CV, Ezquer M, Deis R, Maldonado C, Soaje M: Pituitary changes involved in prolactin secretion induced by mifepristone and naloxone during late pregnancy. Neuroendocrinology 2009;89:200–209.
48.
Steyn FJ, Anderson GM, Grattan DR: Expression of ovarian steroid hormone receptors in tuberoinfundibular dopaminergic neurones during pregnancy and lactation. J Neuroendocrinol 2007;19:788–793.
49.
Guerra-Araiza C, Villamar-Cruz O, Gonzalez-Arenas A, Chavira R, Camacho-Arroyo I: Changes in progesterone receptor isoforms content in the rat brain during the oestrous cycle and after oestradiol and progesterone treatments. J Neuroendocrinol 2003;15:984–990.
50.
Greco B, Allegretto EA, Tetel MJ, Blaustein JD: Coexpression of ER beta with ER alpha and progestin receptor proteins in the female rat forebrain: effects of estradiol treatment. Endocrinology 2001;142:5172–5181.
51.
Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM: Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000;289:1751–1754.
52.
Conneely OM, Mulac-Jericevic B, Lydon JP, De Mayo FJ: Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice. Mol Cell Endocrinol 2001;179:97–103.
53.
Simian M, Bissell MJ, Barcellos-Hoff MH, Shyamala G: Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice. Breast Cancer Res 2009;11:R72.
54.
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 2. New York, Academic Press, 1986.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.